Who is on it, and how far along Every drug ChEMBL records acting on S, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Antibody 12 Protein or peptide 2 Other 6 Phase 39 Casirivimab Casirivimab SponsorPregistry ModalityAntibody ActionInhibitor Open trials4 Imdevimab Imdevimab SponsorPregistry ModalityAntibody ActionInhibitor Open trials4 Bamlanivimab Bamlanivimab SponsorNot known ModalityAntibody ActionInhibitor Open trials1 Cilgavimab Cilgavimab SponsorMediMergent, LLC ModalityAntibody ActionBlocker Open trials1 Tixagevimab Tixagevimab SponsorMediMergent, LLC ModalityAntibody ActionBlocker Open trials1 Amubarvimab Amubarvimab SponsorBrii Biosciences Limited ModalityAntibody ActionInhibitor Open trials0 Ensovibep Ensovibep SponsorMolecular Partners ModalityProtein or peptide ActionInhibitor Open trials0 Etesevimab Etesevimab SponsorNot known ModalityAntibody ActionInhibitor Open trials0 Romlusevimab Romlusevimab SponsorBrii Biosciences Limited ModalityAntibody ActionInhibitor Open trials0 Phase 23 Abdavomeran Abdavomeran SponsorBioNTech SE ModalityOther ActionVaccine antigen Open trials0 Adintrevimab Adintrevimab SponsorInvivyd ModalityAntibody ActionInhibitor Open trials0 Bebtelovimab Bebtelovimab SponsorEli Lilly ModalityAntibody ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 11 of 20 act as: Spike glycoprotein inhibitor; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years SARS-COV-2 virus spike protein Phase 1 Not yet recruiting BMI Korea Aug 27, 2026 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age SARS-COV-2 virus spike protein Phase 4 Recruiting BioNTech SE Jul 28, 2026 A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine SARS-COV-2 virus spike protein Phase 1 Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) Jul 14, 2026 Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia SARS-COV-2 virus spike protein Phase 2 Not yet recruiting National Research Institute of Chinese Medicine, Ministry of Health and Welfare May 13, 2026 A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults Chimpanzee adenovirus encoding SARS-COV-2 spike glycoprotein, SARS-COV-2 virus spike protein Phase 1 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) Apr 17, 2026 Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients Tozinameran Phase 2 Not yet recruiting Fred Hutchinson Cancer Center Feb 5, 2026 A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. SARS-COV-2 virus spike protein Phase 1 / Phase 2 Active, not recruiting SK Bioscience Co., Ltd. Dec 12, 2025 A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 SARS-COV-2 virus spike protein Phase 1 Active, not recruiting University of Melbourne May 11, 2025 Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program. Elasomeran Phase 4 Recruiting Well- Konnect Healthcare Services and Research Firm Jun 4, 2024 Covid-19 and Influenza Oral Vaccine Study SARS-COV-2 virus spike protein Phase 1 Recruiting Vaxine Pty Ltd Apr 9, 2024 Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE Elasomeran — Active, not recruiting ModernaTX, Inc. Mar 27, 2024 Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers Tozinameran Phase 3 Active, not recruiting Cellid Co., Ltd. Aug 15, 2023 COVID-19 Booster Study in Healthy Adults in Australia Elasomeran Phase 3 Active, not recruiting Murdoch Childrens Research Institute Dec 20, 2022 Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial Elasomeran, Tozinameran Phase 3 Active, not recruiting Monash University Sep 27, 2022 The Impact of COVID-19 on Maternal and Neonatal Outcomes Elasomeran — Recruiting Johns Hopkins University Jan 19, 2022 Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Casirivimab, Cilgavimab, Imdevimab, Sotrovimab, Tixagevimab Phase 2 Recruiting University of Oxford Sep 13, 2021 Korea Comirnaty Post-marketing Surveillance Tozinameran — Active, not recruiting Pfizer Sep 2, 2021 COVID-19 International Drug Pregnancy Registry Casirivimab, Imdevimab, Sotrovimab — Recruiting Pregistry Aug 19, 2021 COVID-19 Vaccines Safety Tracking (CoVaST) Elasomeran — Recruiting Masaryk University Apr 8, 2021 Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) Bamlanivimab, Casirivimab, Imdevimab Phase 1 / Phase 2 Recruiting All Natural Medicine Clinic, LLC Mar 10, 2021 AGILE (Early Phase Platform Trial for COVID-19) Sotrovimab Phase 1 / Phase 2 Recruiting University of Liverpool Feb 9, 2021 Randomised Evaluation of COVID-19 Therapy Casirivimab, Imdevimab, Sotrovimab Phase 3 Recruiting University of Oxford May 11, 2020
Show all 22Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4662936 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets